<p>Cullinan Therapeutics, Inc.（纳斯达克代码：CGEM - 获取免费报告）内部人士 Jennifer Michaelson 于 12 月 15 日星期一出售了 995 股公司股票。该股票的平均售价为 11.90 美元，总价值为 11,840.50 美元。出售后，该内部人士持有公司股票 136,878 股，估值约为 1,628,848.20 美元。这代表其持股减少了 0.72%。该交易已在提交给证券交易委员会的文件中披露，相关文件可通过此链接获取。</p>
<p>获取 <strong>Cullinan Therapeutics</strong> 的提醒：</p>
<p>Jennifer Michaelson 最近还进行了以下交易：</p>
<ul>
<li>在 12 月 12 日星期五，Jennifer Michaelson 出售了 2,148 股 Cullinan Therapeutics 股票。该股票的平均售价为 12.38 美元，总价值为 26,592.24 美元。</li>
<li>在 11 月 24 日星期一，Jennifer Michaelson 出售了 4,000 股 Cullinan Therapeutics 股票。该股票的平均售价为 12.30 美元，总价值为 49,200.00 美元。</li>
</ul>
<h2>Cullinan Therapeutics 股票表现</h2>
<p>CGEM 在星期二下跌 0.60 美元，报 10.22 美元。该公司的交易量为 1,140,331 股，而其平均交易量为 646,330 股。该股票的市值为 6.0376 亿美元，市盈率为-3.09，贝塔值为-0.11。该股票的 50 日移动平均价格为 9.09 美元，200 日移动平均价格为 8.08 美元。Cullinan Therapeutics, Inc.的 12 个月低点为 5.68 美元，12 个月高点为 13.33 美元。</p>
<p>Cullinan Therapeutics（纳斯达克代码：CGEM - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告每股收益为-0.77 美元，超出分析师一致预期的-0.95 美元，超出幅度为 0.18 美元。分析师预测 Cullinan Therapeutics, Inc.在当前财政年度的每股收益为-3.04 美元。</p>
<h2>分析师设定新目标价</h2>
<p>CGEM 已成为多份分析师报告的主题。Wedbush 在 12 月 9 日的报告中将 Cullinan Therapeutics 的目标价从 25.00 美元上调至 34.00 美元，并给予该股票 “跑赢大盘” 的评级。华尔街 Zen 在 11 月 22 日的研究报告中将 Cullinan Therapeutics 的评级从 “卖出” 上调至 “持有”。BTIG Research 在 11 月 24 日的研究报告中将 Cullinan Therapeutics 的目标价从 32.00 美元上调至 38.00 美元，并给予该公司 “买入” 评级。HC Wainwright 在 11 月 20 日的研究报告中将 Cullinan Therapeutics 的目标价从 24.00 美元上调至 26.00 美元，并给予该公司 “买入” 评级。最后，摩根士丹利在 8 月 18 日的研究报告中将 Cullinan Therapeutics 的目标价从 35.00 美元下调至 28.00 美元，并对该股票设定了 “增持” 评级。六位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 28.29 美元。</p>
<p><strong>查看我们对 CGEM 的最新股票分析</strong></p>
<h2>对 Cullinan Therapeutics 的对冲基金看法</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Tudor Investment Corp ET AL 在第三季度将其在 Cullinan Therapeutics 的持股增加了 30.9%。Tudor Investment Corp ET AL 目前持有 28,988 股公司股票，价值 172,000 美元，在此期间又购买了 6,850 股。XTX Topco Ltd 在第三季度将其在 Cullinan Therapeutics 的持股增加了 289.8%。XTX Topco Ltd 目前持有 167,979 股公司股票，价值 996,000 美元，在上个季度又购买了 124,884 股。Qube Research &amp; Technologies Ltd 在第三季度将其在 Cullinan Therapeutics 的持股增加了 127.1%。Qube Research &amp; Technologies Ltd 目前持有 152,409 股公司股票，价值 904,000 美元，在此期间又购买了 85,290 股。Prelude Capital Management LLC 在第三季度将其在 Cullinan Therapeutics 的持股增加了 201.2%。Prelude Capital Management LLC 目前持有 48,652 股公司股票，价值 289,000 美元，在此期间又购买了 32,500 股。最后，Millennium Management LLC 在第三季度将其在 Cullinan Therapeutics 的持股增加了 7.8%。Millennium Management LLC 目前持有 550,471 股公司股票，价值 3,264,000 美元，在上个季度又购买了 39,643 股。对冲基金和其他机构投资者持有该公司 86.31% 的股票。</p>
<h2>关于 Cullinan Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Cullinan Therapeutics, Inc.是一家生物制药公司，专注于为美国癌症患者开发肿瘤治疗药物。该公司的主导项目包括 CLN-619，这是一种单克隆抗体，目前正在进行针对实体肿瘤的 I 期临床试验。其开发组合还包括 CLN-049，这是一种人源化双特异性抗体，目前正在进行针对急性髓性白血病或骨髓增生异常综合症的 I 期临床试验；CLN-418，这是一种人源化双特异性免疫激活剂，目前正在进行针对多种实体肿瘤的 I 期临床试验；以及 Zipalertinib，这是一种可生物利用的小分子，用于治疗非小细胞肺癌患者。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 Cullinan Therapeutics</li>
<li>支撑与阻力的基础知识</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
<li>如何在 5 个简单步骤中做空股票</li>
<li>聪明的钱正在购买汽车供应商，而不是汽车品牌</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>牛肉价格上涨已成定局：2026 年最佳牛排馆股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Cullinan Therapeutics 吗？</h2>
<p>在考虑 Cullinan Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Cullinan Therapeutics 并不在名单上。</p>
<p>虽然 Cullinan Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CGEM

<p>Cullinan Therapeutics 的内部人士 Jennifer Michaelson 出售了 995 股，每股价格为 11.90 美元，总计 11,840.50 美元。出售后，她持有 136,878 股，持股比例减少了 0.72%。该交易已在 SEC 文件中披露。最近的交易包括以 12.38 美元出售 2,148 股和以 12.30 美元出售 4,000 股。该股票最近的表现显示价格下降至 10.22 美元，市值为 6.0376 亿美元。分析师设定了新的价格目标，普遍评级为 “适度买入”，平均目标价为 28.29 美元</p>

<p>Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 995 shares of the company's stock in a transaction on Monday, December 15th. The stock was sold at an average price of $11.90, for a total value of $11,840.50. Following the sale, the insider owned 136,878 shares of the company's stock, valued at approximately $1,628,848.20. This represents a 0.72% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink.</p>
<div class="lb-trans"><p>Cullinan Therapeutics, Inc.（纳斯达克代码：CGEM - 获取免费报告）内部人士 Jennifer Michaelson 于 12 月 15 日星期一出售了 995 股公司股票。该股票的平均售价为 11.90 美元，总价值为 11,840.50 美元。出售后，该内部人士持有公司股票 136,878 股，估值约为 1,628,848.20 美元。这代表其持股减少了 0.72%。该交易已在提交给证券交易委员会的文件中披露，相关文件可通过此链接获取。</p>
</div><p>Get <strong>Cullinan Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cullinan Therapeutics</strong> 的提醒：</p>
</div><p>Jennifer Michaelson also recently made the following trade(s):</p>
<div class="lb-trans"><p>Jennifer Michaelson 最近还进行了以下交易：</p>
</div><ul>
<li>On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.38, for a total value of $26,592.24.</li>
<li>On Monday, November 24th, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.30, for a total value of $49,200.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 12 日星期五，Jennifer Michaelson 出售了 2,148 股 Cullinan Therapeutics 股票。该股票的平均售价为 12.38 美元，总价值为 26,592.24 美元。</li>
<li>在 11 月 24 日星期一，Jennifer Michaelson 出售了 4,000 股 Cullinan Therapeutics 股票。该股票的平均售价为 12.30 美元，总价值为 49,200.00 美元。</li>
</ul>
</div><h2>Cullinan Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Cullinan Therapeutics 股票表现</h2>
</div><p>CGEM traded down $0.60 on Tuesday, hitting $10.22. The company had a trading volume of 1,140,331 shares, compared to its average volume of 646,330. The stock has a market capitalization of $603.76 million, a price-to-earnings ratio of -3.09 and a beta of -0.11. The stock has a fifty day moving average price of $9.09 and a 200-day moving average price of $8.08. Cullinan Therapeutics, Inc. has a 12-month low of $5.68 and a 12-month high of $13.33.</p>
<div class="lb-trans"><p>CGEM 在星期二下跌 0.60 美元，报 10.22 美元。该公司的交易量为 1,140,331 股，而其平均交易量为 646,330 股。该股票的市值为 6.0376 亿美元，市盈率为-3.09，贝塔值为-0.11。该股票的 50 日移动平均价格为 9.09 美元，200 日移动平均价格为 8.08 美元。Cullinan Therapeutics, Inc.的 12 个月低点为 5.68 美元，12 个月高点为 13.33 美元。</p>
</div><p>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.18. Analysts forecast that Cullinan Therapeutics, Inc. will post -3.04 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cullinan Therapeutics（纳斯达克代码：CGEM - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告每股收益为-0.77 美元，超出分析师一致预期的-0.95 美元，超出幅度为 0.18 美元。分析师预测 Cullinan Therapeutics, Inc.在当前财政年度的每股收益为-3.04 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>CGEM has been the topic of several analyst reports. Wedbush lifted their price target on shares of Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an &#34;outperform&#34; rating in a report on Tuesday, December 9th. Wall Street Zen raised Cullinan Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 22nd. BTIG Research upped their target price on Cullinan Therapeutics from $32.00 to $38.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, November 24th. HC Wainwright increased their price target on Cullinan Therapeutics from $24.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, November 20th. Finally, Morgan Stanley dropped their price target on Cullinan Therapeutics from $35.00 to $28.00 and set an &#34;overweight&#34; rating on the stock in a research note on Monday, August 18th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $28.29.</p>
<div class="lb-trans"><p>CGEM 已成为多份分析师报告的主题。Wedbush 在 12 月 9 日的报告中将 Cullinan Therapeutics 的目标价从 25.00 美元上调至 34.00 美元，并给予该股票 “跑赢大盘” 的评级。华尔街 Zen 在 11 月 22 日的研究报告中将 Cullinan Therapeutics 的评级从 “卖出” 上调至 “持有”。BTIG Research 在 11 月 24 日的研究报告中将 Cullinan Therapeutics 的目标价从 32.00 美元上调至 38.00 美元，并给予该公司 “买入” 评级。HC Wainwright 在 11 月 20 日的研究报告中将 Cullinan Therapeutics 的目标价从 24.00 美元上调至 26.00 美元，并给予该公司 “买入” 评级。最后，摩根士丹利在 8 月 18 日的研究报告中将 Cullinan Therapeutics 的目标价从 35.00 美元下调至 28.00 美元，并对该股票设定了 “增持” 评级。六位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 28.29 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on CGEM</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CGEM 的最新股票分析</strong></p>
</div><h2>Hedge Funds Weigh In On Cullinan Therapeutics</h2>
<div class="lb-trans"><h2>对 Cullinan Therapeutics 的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL lifted its position in Cullinan Therapeutics by 30.9% during the 3rd quarter. Tudor Investment Corp ET AL now owns 28,988 shares of the company's stock worth $172,000 after acquiring an additional 6,850 shares during the period. XTX Topco Ltd raised its stake in shares of Cullinan Therapeutics by 289.8% in the third quarter. XTX Topco Ltd now owns 167,979 shares of the company's stock worth $996,000 after purchasing an additional 124,884 shares during the last quarter. Qube Research &amp; Technologies Ltd lifted its holdings in shares of Cullinan Therapeutics by 127.1% during the third quarter. Qube Research &amp; Technologies Ltd now owns 152,409 shares of the company's stock worth $904,000 after purchasing an additional 85,290 shares during the period. Prelude Capital Management LLC lifted its holdings in shares of Cullinan Therapeutics by 201.2% during the third quarter. Prelude Capital Management LLC now owns 48,652 shares of the company's stock worth $289,000 after purchasing an additional 32,500 shares during the period. Finally, Millennium Management LLC boosted its position in Cullinan Therapeutics by 7.8% in the third quarter. Millennium Management LLC now owns 550,471 shares of the company's stock valued at $3,264,000 after buying an additional 39,643 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Tudor Investment Corp ET AL 在第三季度将其在 Cullinan Therapeutics 的持股增加了 30.9%。Tudor Investment Corp ET AL 目前持有 28,988 股公司股票，价值 172,000 美元，在此期间又购买了 6,850 股。XTX Topco Ltd 在第三季度将其在 Cullinan Therapeutics 的持股增加了 289.8%。XTX Topco Ltd 目前持有 167,979 股公司股票，价值 996,000 美元，在上个季度又购买了 124,884 股。Qube Research &amp; Technologies Ltd 在第三季度将其在 Cullinan Therapeutics 的持股增加了 127.1%。Qube Research &amp; Technologies Ltd 目前持有 152,409 股公司股票，价值 904,000 美元，在此期间又购买了 85,290 股。Prelude Capital Management LLC 在第三季度将其在 Cullinan Therapeutics 的持股增加了 201.2%。Prelude Capital Management LLC 目前持有 48,652 股公司股票，价值 289,000 美元，在此期间又购买了 32,500 股。最后，Millennium Management LLC 在第三季度将其在 Cullinan Therapeutics 的持股增加了 7.8%。Millennium Management LLC 目前持有 550,471 股公司股票，价值 3,264,000 美元，在上个季度又购买了 39,643 股。对冲基金和其他机构投资者持有该公司 86.31% 的股票。</p>
</div><h2>About Cullinan Therapeutics</h2>
<div class="lb-trans"><h2>关于 Cullinan Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.</p>
<div class="lb-trans"><p>Cullinan Therapeutics, Inc.是一家生物制药公司，专注于为美国癌症患者开发肿瘤治疗药物。该公司的主导项目包括 CLN-619，这是一种单克隆抗体，目前正在进行针对实体肿瘤的 I 期临床试验。其开发组合还包括 CLN-049，这是一种人源化双特异性抗体，目前正在进行针对急性髓性白血病或骨髓增生异常综合症的 I 期临床试验；CLN-418，这是一种人源化双特异性免疫激活剂，目前正在进行针对多种实体肿瘤的 I 期临床试验；以及 Zipalertinib，这是一种可生物利用的小分子，用于治疗非小细胞肺癌患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Cullinan Therapeutics</li>
<li>The Basics of Support and Resistance</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
<li>How to Short a Stock in 5 Easy Steps</li>
<li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Higher Beef Prices Are Here: Best Steakhouse Stocks for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Cullinan Therapeutics</li>
<li>支撑与阻力的基础知识</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
<li>如何在 5 个简单步骤中做空股票</li>
<li>聪明的钱正在购买汽车供应商，而不是汽车品牌</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>牛肉价格上涨已成定局：2026 年最佳牛排馆股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=CGEM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Cullinan Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cullinan Therapeutics 吗？</h2>
</div><p>Before you consider Cullinan Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cullinan Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Cullinan Therapeutics 并不在名单上。</p>
</div><p>While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cullinan Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cullinan Therapeutics (NASDAQ:CGEM) 内部人士 Jennifer Michaelson 出售了 995 股股票